Group 1: Market Overview - Stocks are rallying on expectations of a 25 basis points interest rate cut by the Federal Reserve in September, which is anticipated to positively impact corporate earnings [1] - Lower interest rates may lead to higher inflation and keep rates above the Fed's target of 2%, while geopolitical events are increasing, prompting central banks to buy gold and speculative investors to purchase Bitcoin and other cryptocurrencies [2] Group 2: Coca-Cola Company - Coca-Cola has a dividend yield of 3.07% with an annual dividend of $2.04 and a 64-year track record of dividend increases, maintaining a payout ratio of 72.34% [3][5] - Despite a 6.37% increase in 2025, Coca-Cola's performance is about 50% lower than the S&P 500's 13% gain, but the dividend yield remains a significant factor for investors [3] - The company continues to grow revenue and earnings by diversifying its portfolio beyond soft drinks into sports drinks, teas, and enhanced water beverages [4] Group 3: Johnson & Johnson - Johnson & Johnson has a dividend yield of 2.95% with an annual dividend of $5.20 and a 64-year history of dividend increases, maintaining a payout ratio of 55.61% [6][7] - The company has become leaner and more efficient, focusing on pharmaceuticals and medical technology, particularly in oncology and immunotherapy [8] - Johnson & Johnson's stock has increased by about 22% in 2025 and is trading at around 16 times forward earnings, which is a discount to its historical averages [9] Group 4: Prologis - Prologis has a dividend yield of 3.56% with an annual dividend of $4.04 and a 12-year track record of dividend increases, although it has a high payout ratio of 109.49% [10][12] - As the world's largest industrial real estate investment trust (REIT), Prologis specializes in logistics and warehouse properties, which are expected to have stable occupancy rates as consumer sentiment improves [11] - The company is pivoting into sectors like sustainable energy and data center development, with predictable cash flows from long-term leases and strong tenant demand [12]

Financial Data and Key Metrics Changes - The company reported a revenue of $3,600,000,000, an increase of 8.3% compared to the previous year [12][9] - Underlying EBITDA reached $95,200,000, up $2,800,000 or about 3% year-on-year [13][12] - Net profit after tax was $31,200,000, with a statutory result of $20,600,000 [9][10] - Free operating cash flow was negative at $11,000,000, significantly impacted by receivables from a group of pharmacies [19][20] Business Line Data and Key Metrics Changes - Revenue from Australia and New Zealand grew to $3,500,000,000, an increase of 8% [21] - Gross margin in Australia and New Zealand was $277,900,000, up 5% [21] - The Asian market saw revenue increase from $84,200,000 to $101,000,000, a growth of 20% [23] Market Data and Key Metrics Changes - Strong growth was noted in Thailand's aesthetics division, contributing to the overall revenue increase in Asia [24] - The imaging business performed solidly despite some market headwinds [24] - Modest growth was observed in the Philippines due to declining contracts [24] Company Strategy and Development Direction - The company aims to continue its growth strategy in Asia following the merger with Paragon Care Group [2][4] - Focus on operational efficiencies and integration of businesses onto a single platform [26][29] - Emphasis on organic growth through investments in sales teams and new business opportunities in dental, robotics, and aesthetics [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $12,000,000 in synergies for FY '26, building on the $5,000,000 achieved in FY '25 [26][30] - The competitive landscape in retail pharmacy is evolving, with expectations for continued growth despite challenges [34][35] - Future profitability is expected to improve as synergies are realized and new opportunities are explored [30] Other Important Information - The company completed a refinancing with Scott Pak, increasing local borrowing capacity and reducing interest costs [19][20] - The acquisition of AHP Dental is expected to provide a step into the dental market, with an anticipated EBITDA contribution of around $1,000,000 for FY '26 [46][45] Q&A Session Summary Question: Outlook on revenue and profit for next year - Management indicated that revenue growth would be positive but not necessarily at the same rate as FY '25, suggesting single mid-digit growth rates [33] Question: Competitive landscape in retail pharmacy - Management noted the difficulty in predicting the competitive landscape due to market evolution, particularly following significant mergers [34] Question: Clarification on integration costs in EBITDA - Integration costs were clarified to be excluded from the underlying EBITDA figure [36][37] Question: M&A pipeline and net debt to EBITDA ratio - Management expressed willingness to increase net debt to pursue opportunities, particularly in Asia [38] Question: Details on synergies and cost savings from refinancing - Management confirmed that the $2,000,000 cost saving from refinancing is separate from the $12,000,000 synergy target for FY '26 [43][44] Question: Profitability of recent acquisitions - The AHP Dental acquisition is expected to contribute modestly to EBITDA but offers growth potential in the dental market [46] Question: Focus on growth opportunities in Asia - Management confirmed ongoing efforts to explore acquisitions in Asia that align with current operations [49] Question: Future financing arrangements with Scott Pak - Management indicated a commitment to maintaining the lowest possible cost of funds and flexibility in financing arrangements [57][58]